Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net income (loss)	$ 4,795,000	$ (4,640,000)
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	1,454,000	373,000
Amortization of intangible assets	2,100,000	465,000
Non cash lease expense	455,000	361,000
Stock-based compensation	3,818,000	2,179,000
Loss from equity method investment in SAVSU	0	739,000
Gain on acquisition of SAVSU	0	(10,108,000)
Change in fair value of investments	(1,110,000)	0
Change in fair value of contingent consideration	(1,528,000)	0
Change in fair value of warrant liability	(4,467,000)	14,949,000
Stock issued for services	30,000	0
Other	9,000	15,000
Change in operating assets and liabilities
Accounts receivable, trade, net	(820,000)	(372,000)
Inventories	(65,000)	(1,730,000)
Prepaid expenses and other current assets	68,000	(272,000)
Accounts payable	(604,000)	377,000
Other payables	(406,000)	(87,000)
Accrued compensation and other current liabilities	689,000	65,000
Other	(30,000)	(98,000)
Net cash provided by operating activities	4,388,000	2,216,000
Cash flows from investing activities
Investment in iVexSol	0	(1,000,000)
Purchase of property and equipment	(370,000)	(356,000)
Purchase of assets held for rent, net	(1,791,000)	(453,000)
Proceeds from sale of equipment	3,000	0
Net cash used in investing activities	(2,658,000)	(12,997,000)
Cash flows from financing activities
Proceeds from PPP Loan	2,175,000	0
Payoff of PPP Loan	(2,175,000)	0
Payments of contingent consideration	(483,000)	0
Proceeds from sale of common stock, net of $6.2 million of costs	100,251,000	0
Proceeds from exercise of common stock options	1,028,000	841,000
Proceeds from exercise of warrants	40,000	553,000
Payments of costs related to stock issuance	0	(44,000)
Other	(30,000)	(21,000)
Net cash provided by financing activities	100,806,000	1,329,000
Net increase (decrease) in cash, cash equivalents and restricted cash	102,536,000	(9,452,000)
Cash, cash equivalents and restricted cash - beginning of period	6,448,000	30,657,000
Cash, cash equivalents and restricted cash - end of period	108,984,000	21,205,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassed from warrant liability to common stock	33,111,000	0
Reclassification of warrant liability to equity upon exercise	110,000	1,694,000
Purchase of property & equipment not yet paid	29,000	146,000
Financing costs paid in a prior period	130,000	0
Deferred financing costs not yet paid	0	53,000
Purchase of equipment with debt	270,000	0
Stock issued as consideration to acquire SAVSU	0	19,932,000
Prepayment of Services [Member]
Non-cash investing and financing activities
Stock issued	30,000	0
Bonus Consideration [Member]
Non-cash investing and financing activities
Stock issued	314,000	0
SciSafe Holdings, Inc [Member]
Cash flows from investing activities
Payments related to the acquisition, net of cash acquired	(500,000)	0
SAVSU [Member]
Cash flows from investing activities
Payments related to the acquisition, net of cash acquired	0	1,251,000
Astero [Member]
Cash flows from investing activities
Payments related to the acquisition, net of cash acquired	$ 0	$ (12,439,000)